Citigroup
ATNM icon

Citigroup’s Actinium Pharmaceuticals ATNM Stock Holding History

Citigroup’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$675 Buy
678
+247
+57% +$294 ﹤0.01% 5513
2025
Q4 		$586 Sell
431
-854
-66% -$1.25K ﹤0.01% 5576
2025
Q3 		$2.06K Sell
1,285
-13,831
-91% -$22.5K ﹤0.01% 5474
2025
Q2 		$21.2K Sell
15,116
-7,578
-33% -$11.3K ﹤0.01% 5060
2025
Q1 		$36.5K Sell
22,694
-2,614
-10% -$3.32K ﹤0.01% 4964
2024
Q4 		$31.9K Buy
25,308
+3,559
+16% +$5.52K ﹤0.01% 5195
2024
Q3 		$40.9K Buy
21,749
+15,152
+230% +$59.9K ﹤0.01% 5065
2024
Q2 		$48.8K Buy
6,597
+1,946
+42% +$16K ﹤0.01% 4595
2024
Q1 		$36.4K Buy
4,651
+725
+18% +$4.66K ﹤0.01% 4783
2023
Q4 		$19.9K Buy
3,926
+3,906
+19,530% +$20.1K ﹤0.01% 4989
2023
Q3 		$118 Sell
20
-7,726
-100% -$51.4K ﹤0.01% 5388
2023
Q2 		$57.5K Sell
7,746
-42,065
-84% -$358K ﹤0.01% 4556
2023
Q1 		$471K Buy
49,811
+659
+1% +$6.96K ﹤0.01% 3165
2022
Q4 		$523K Buy
49,152
+41,523
+544% +$421K ﹤0.01% 3133
2022
Q3 		$56K Buy
+7,629
New +$47.4K ﹤0.01% 4337
2020
Q4 		– Sell
-1,005
Closed -$10K – 7355
2020
Q3 		$10K Buy
+1,005
New +$11.1K ﹤0.01% 6597
2016
Q2 		– Sell
-4
Closed – – 7064
2016
Q1 		$0 Buy
+4
New +$253 ﹤0.01% 7446
2015
Q2 		– Sell
-146
Closed -$11K – 7503
2015
Q1 		$11K Buy
146
+25
+21% +$2.97K ﹤0.01% 6409
2014
Q4 		$21K Buy
121
+96
+384% +$18.2K ﹤0.01% 6182
2014
Q3 		$5K Buy
25
+19
+317% +$3.77K ﹤0.01% 6547
2014
Q2 		$1K Buy
+6
New +$2K ﹤0.01% 6887

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's ATNM Position: Q1 2026 in Review

Citigroup increased its Actinium Pharmaceuticals (ATNM) stake by 57% in Q1 2026, buying an estimated $294 and bringing the position to 678 shares worth $675. The position accounts for ﹤0.01% of the portfolio, ranked #5513.

Citigroup first reported a position in ATNM in Q2 2014 and has held it in 21 quarters since. The position peaked at $523K in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Citigroup held 678 shares of Actinium Pharmaceuticals worth $675 as of Q1 2026.
  • Citigroup bought 247 Actinium Pharmaceuticals shares in Q1 2026, an estimated $294.
  • Actinium Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5513 holding.
  • Citigroup first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 21 quarters since.
  • Citigroup's Actinium Pharmaceuticals position peaked at $523K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.